Abstract
The methods and conditions for the synthesis of the main metabolite of the selective anxiolytic afobazole, 2-[2-(3-oxomorpholin-4-yl)ethylthio]-5-ethoxybenzimidazole, and its analogs are developed. It is shown that the main metabolite demonstrates an anxiolytic effect in a dose range similar to that of afobazole. It is found that the psychopharmacological profile of the other synthesized compounds (analogs) is characterized by a less pronounced anxiolytic component.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
